glp 1 risk of cancer GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials - Silverii - 2025 - Diabetes, Obesity and Metabolism

Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study

26.28

★★★★☆4.8 (126)

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology's annual meeting. The

25.37

★★★★★4.9 (98)

Could popular diabetes and weight-loss drugs influence blood cancer risk? GLP-1 receptor agonists—drugs like Ozempic and Wegovy ( Novo Nordisk Foundation ) —are widely prescribed for type 2 diabetes and weight loss

25.15

★★★★★5.0 (157)

Both GLP-1 Receptor Agonists and Bariatric Surgery Lower the Risk of Weight-Related Cancer in Patients With Obesity

26.35

★★★★★4.7 (84)

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence | Biomarker Research

25.19

★★★★★4.9 (203)

Could GLP-1 medications help slow cancer progression? A new Cleveland Clinic study found those taking GLP-1s were less likely to develop stage IV disease in several cancer types, when compared to patients

27.12

★★★★★5.0 (176)

Could popular diabetes and weight-loss drugs influence blood cancer risk? GLP-1 receptor agonists—drugs like Ozempic and Wegovy ( Novo Nordisk Foundation ) —are widely prescribed for type 2 diabetes and weight loss

28.30

★★★★★4.8 (132)